Eli Lilly and Co at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hi, I'm Louise Chen, the large-cap biopharma analyst here at Cantor. Thank you for joining us today for a virtual fireside chat with Eli Lilly. Lilly is one of the top-performing pharma companies in the sector with a robust portfolio of fast-growing products and a pipeline of first-in-class and/or best-in-class drugs. We think the company's earnings profile continues to look favorable when compared to those of its peers. Its margin expansion profile represents one of the strongest in the pharma industry, with a potential for mid-teens EPS growth. Lilly is entering a period of earnings growth, unencumbered by large loss of exclusivities and bolstered by multiple pipeline readouts of its first-in-class and/or best-in-class compounds. Therefore, we are thrilled to have with us today, CFO, Josh Smiley, to talk about the business.
Questions & Answers
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
